Xenon Pharmaceuticals Inc.
NASDAQ:XENE · NASDAQ Global Market
-$0.29 today
Vol 1.90M · Avg 1.16M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $545.9M |
| Short-term Investments | $548.9M |
| Receivables | $1.2M |
| Other Current | $10.7M |
| Total Current Assets | $1.1B |
| PP&E (Net) | $14.6M |
| Long-term Investments | $244.9M |
| Tax Assets | $12.4M |
| Other Non-current | $8.3M |
| Total Non-current Assets | $280.2M |
| Total Assets | $1.4B |
Analysis
Selected assets total $1.4B for Latest. The largest visible component is Short-term Investments at $548.9M, about 39.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $199.2M +39.6% | $142.7M -4.0% | $148.6M +159.7% | $57.2M -67.4% | $175.7M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $349.7M -27.8% | $484.2M -1.1% | $489.4M -8.5% | $534.8M +42.2% | $376.1M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.4M -6.7% | $1.5M +68.1% | $874.0K -11.4% | $986.0K -64.3% | $2.8M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $10.4M +50.8% | $6.9M +14.7% | $6.0M -16.9% | $7.2M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $560.6M -11.7% | $635.3M -1.5% | $645.0M +7.4% | $600.3M +7.4% | $559.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $15.3M -15.8% | $18.2M -3.3% | $18.8M +11.5% | $16.9M +35.0% | $12.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $37.2M -70.9% | $127.5M -56.5% | $292.8M +127.5% | $128.7M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $361.4M +3638.6% | $9.7M +1105.2% | $802.0K +57.6% | $509.0K +9.5% | $465.0K | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $7.2M -4.6% | $7.5M +1.4% | $7.4M -4.6% | $7.8M | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $421.0M +158.5% | $162.9M -49.1% | $319.8M +107.9% | $153.8M +1084.6% | $13.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $981.7M +23.0% | $798.1M -17.3% | $964.8M +27.9% | $754.1M +31.8% | $572.0M | $13.3B | $11.9B | $10.6B |
| Account Payables | $3.9M -23.4% | $5.1M -41.0% | $8.6M +1.3% | $8.5M +122.0% | $3.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.5M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $5.7M | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $21.6M +117.6% | $9.9M +2761.1% | $347.0K -94.0% | $5.8M -2.0% | $5.9M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $41.8M +17.4% | $35.6M +30.5% | $27.3M +20.1% | $22.7M +58.5% | $14.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $348.5M | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $3.2M | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $358.1M +4583.7% | $7.6M -20.4% | $9.6M -3.4% | $9.9M +30.0% | $7.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $399.9M +824.9% | $43.2M +17.2% | $36.9M +12.9% | $32.6M +48.6% | $22.0M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.6B +9.7% | $1.5B +1.4% | $1.4B +34.9% | $1.1B +36.0% | $783.2M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.2B -38.5% | -$899.5M -35.2% | -$665.1M -37.8% | -$482.7M -35.1% | -$357.4M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $335.0K +120.8% | -$1.6M -1993.5% | -$77.0K +97.4% | -$3.0M -203.0% | -$990.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $581.8M -22.9% | $754.9M -18.6% | $927.9M +28.6% | $721.5M +31.2% | $550.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $7.9M -11.9% | $9.0M -17.3% | $10.9M +4.5% | $10.4M +26.4% | $8.3M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$191.2M -43.0% | -$133.7M +2.9% | -$137.7M -194.3% | -$46.8M +72.0% | -$167.4M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.64B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.44B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.38B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Celcuity Inc.
NASDAQ:CELC
$4.07B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.69B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Ascentage Pharma Group International
NASDAQ:AAPG
$403.00M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does XENE have?
Xenon Pharmaceuticals Inc. (XENE) reported $199.16M in cash and equivalents in fiscal 2025.
How much debt does XENE carry?
Xenon Pharmaceuticals Inc. (XENE) reported $7.94M of total debt, with net debt of -$191,219,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.